Taken together, our results suggest that ATL III ameliorates NAFLD by activating multiple signaling pathways involved in lipid accumulation (LKB1 and AMPK), oxidative stress (SIRT3 and Nrf2) and fatty acid oxidation (CPT1A and PGC1α). The gene discussed is CPT1A; the disease is metabolic dysfunction-associated steatotic liver disease.